| Title |
Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications
|
|---|---|
| Published in |
Current Treatment Options in Neurology, April 2017
|
| DOI | 10.1007/s11940-017-0456-3 |
| Pubmed ID | |
| Authors |
Nicolas Collongues, Laure Michel, Jérôme de Seze |
| Abstract |
Biotherapy represents an innovative therapeutic approach that includes immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell transplants. Their development helps to cross the bridge from bench to bedside and brings new hope of a cure for severe diseases in different fields of medicine. In neurology, a growing range of applications is being developed for these medications. Valuable results are now available in the field of autoimmunity, neuro-oncology, paraneoplastic manifestations, and neurodegenerative disorders. In this review, we examine the current and future applications of biotherapy in the field of inflammation of the central nervous system. We demonstrate its contribution in clinical practice, where it has enabled a significant level of effectiveness to be achieved. Indeed, the efficacy of these new biodrugs provides a solution for patients refractory to standard therapies, such as intravenous immunoglobulins in limbic encephalitis, plasma exchanges in neuromyelitis optica and anti-CD20 monoclonal antibodies in multiple sclerosis. They also mark the first steps towards individualized medicine. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 3% |
| Unknown | 31 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 19% |
| Student > Master | 5 | 16% |
| Researcher | 4 | 13% |
| Other | 3 | 9% |
| Student > Doctoral Student | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 9 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 31% |
| Biochemistry, Genetics and Molecular Biology | 4 | 13% |
| Neuroscience | 4 | 13% |
| Agricultural and Biological Sciences | 1 | 3% |
| Social Sciences | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 9 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2017.
All research outputs
#14,427,926
of 23,577,654 outputs
Outputs from Current Treatment Options in Neurology
#285
of 474 outputs
Outputs of similar age
#168,669
of 311,195 outputs
Outputs of similar age from Current Treatment Options in Neurology
#8
of 16 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 474 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,195 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.